Government’s focus on R&D activities in healthcare and increasing approvals for manufacture of generic drugs to drive United States soft tissue sarcoma market
According to TechSci Research report, “United States Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast & Opportunities, 2025”, the market is expected to witness a robust CAGR during the forecast period as the government is focusing on investing in research and development activities to find the better treatments for different types of cancer, including soft tissue sarcoma. The rising awareness among people about such diseases and increasing per capita disposable income is also making United States a favorable market for companies manufacturing drugs for soft tissue sarcoma. Additionally, with increasing prevalence of various types of soft tissue sarcoma in United States, the market is poised to undergo rapid growth until 2025.
Moreover, the country is witnessing increase in approval for manufacture of generic drugs, which is providing a major boost to soft tissue sarcoma market. The availability of advanced healthcare system and rise in quality patient care are some other key factors fueling the market growth. Also, patent expiry of branded drugs and entry of new manufacturers are some other factors anticipated to further drive United States soft tissue sarcoma market in the coming years.
However, the market is also facing some major restrain. U.S. FDA has reported significant shortage of some essential drugs such as doxorubicin which is majorly employed in chemotherapy, thereby acting as a major challenge for the manufacturers. Also, high failure rate in clinical trials and side effects associated with cancer therapy are some other key factors hampering the growth of United States soft tissue sarcoma market.
Browse XX market data Tables and XX Figures spread through XXX Pages and an in-depth TOC on “United States Soft Tissue Sarcoma Market”
https://www.techsciresearch.com/report/united-states-soft-tissue-sarcoma-market/4856.html
The United States soft tissue sarcoma market is segmented based on treatment, disease type, end user and region. Based on end user, the market is segmented into hospitals, oncology center, long term care center. Here, the oncology center segment is undergoing fastest growth and is expected to dominate the market until 2025. The advance treatment offered by these centers is one of the key reasons behind its high growth.
Based on treatment, the United States soft tissue sarcoma market is segmented into targeted therapy, chemotherapy, anti-angiogenesis drug and radiation therapy. Among these, the high success rate of chemotherapy makes them the dominating segment in market. It uses a combination of various anti-cancer drugs and is being extensively carried out by oncology specialists.
Major players operating in the United States soft tissue sarcoma market include GlaxoSmithKline LLC, Eli Lilly and Company, Pfizer, Inc., Bristol-Myers Squibb Co, Hoffmann-La Roche Inc, Johnson & Johnson Services, Inc., Teva Pharmaceuticals USA Inc, Celgene Corporation, BioHorizons, Zimmer Biomet Holdings Inc and MiMedx Group Inc. Leading manufacturers are focusing on new product launches and research & development activities to enhance their market share.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4856
Customers can also request for 10% free customization on this report.
“United States is experiencing a significant rise in patients suffering from soft tissue sarcoma. The Trump government is however increasing spending on healthcare sector to provide better treatments and facilitate new drug development in the country. Additionally, the advent of advanced therapies such as biological and targeted therapies is providing a major boost to the market. Moreover, the manufacturers are using latest technologies in order to provide better treatments and drugs for soft tissue sarcoma,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“United States Soft Tissue Sarcoma Market By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drug, Radiation Therapy), By Disease Type (Local Sarcoma, Regional Sarcoma, Metastatic Sarcoma), By End User (Hospitals, Oncology Center, Long Term Care Center), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of United States soft tissue sarcoma market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in United States soft tissue sarcoma market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]